SecBot SecBot
Insider Cluster (4 insiders) ·Filed Jul 7, 2026

CYTK

CYTOKINETICS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago
Insider cluster: 3 insiders, $2.3M total
Actionable Insight • Neutral

The insider selling is routine and immaterial in size. Monitor for any upcoming clinical or regulatory catalysts (CYTK is a biotech) that could drive the stock, but this cluster provides no actionable edge.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$84.88
T+0 close · Jul 7, 2026 · via day close
Latest settled
−22.69%
T+60 · $65.62
Vs SPY
−25.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 8 $84.88entry
  2. T+1 · 4mo ago +1.40%α +0.56% · $86.07
  3. T+5 · 4mo ago −2.66%α −3.92% · $82.62
  4. T+20 · 3mo ago −7.10%α −10.38% · $78.85
  5. T+60 · 7w ago −22.69%α −25.18% · $65.62
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Four CYTK insiders (CEO, CFO, CCO, EVP R&D) sold a total of $2.32M in shares over a one-week window, but this represents only ~0.02% of the company's $10.6B market cap. The sales are trivial in proportion to company size and include a routine cashless exercise by the EVP R&D. No material signal for the stock.

Key Financial Metrics

Direction
selling
Total Value
$2.3M
Insiders
4

Key Facts

  • Total insider sales of $2.32M over 7 days (4 transactions)
  • Sales represent ~0.02% of CYTK's $10.6B market cap
  • CEO Robert Blum sold $637K, CCO Andrew Callos sold $1.29M, CFO Sung Lee sold $98K, EVP R&D Fady Malik sold $303K (including derivative exercise)
  • All sales are open-market or cashless exercises; no pattern suggests material non-public information

Financial Impact

Insider sales of $2.32M, negligible relative to $10.6B market cap

insider ownership

Risk Factors

  • Insider sales could increase if the stock continues to appreciate, but current levels are trivial

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CYTK-1783490503419

Track record

46 reports on CYTK

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $56.13 +4.41% settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $56.13 +0.00% settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $56.13 +1.04% settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $56.13 −11.75% settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $56.13 −9.51% settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens Wed (11h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 8, 2026